Hoshiai H - Search Results

1

Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer.

Watanabe Y, Koike E, Nakai H, Etoh T, Hoshiai H. Watanabe Y, et al. Among authors: hoshiai h. Int J Clin Oncol. 2008 Aug;13(4):345-8. doi: 10.1007/s10147-008-0765-3. Epub 2008 Aug 15. Int J Clin Oncol. 2008. PMID: 18704636 Clinical Trial.

2

Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer.

Watanabe Y, Nakai H, Ueda H, Hoshiai H. Watanabe Y, et al. Among authors: hoshiai h. Gynecol Oncol. 2005 Feb;96(2):323-9. doi: 10.1016/j.ygyno.2004.09.029. Gynecol Oncol. 2005. PMID: 15661216 Clinical Trial.

3

Feasibility of concurrent cisplatin use during primary and adjuvant chemoradiation therapy: a phase I study in Japanese patients with cancer of the uterine cervix.

Watanabe Y, Nakai H, Shimaoka M, Tobiume T, Tsuji I, Hoshiai H. Watanabe Y, et al. Among authors: hoshiai h. Int J Clin Oncol. 2006 Aug;11(4):309-13. doi: 10.1007/s10147-006-0567-4. Int J Clin Oncol. 2006. PMID: 16937305 Clinical Trial.

4

Hypoxia inducible factor 1-alpha expression as a factor predictive of efficacy of taxane/platinum chemotherapy in advanced primary epithelial ovarian cancer.

Nakai H, Watanabe Y, Ueda H, Hoshiai H. Nakai H, et al. Among authors: hoshiai h. Cancer Lett. 2007 Jun 18;251(1):164-7. doi: 10.1016/j.canlet.2006.11.017. Epub 2007 Jan 9. Cancer Lett. 2007. PMID: 17215078

5

A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer.

Watanabe Y, Ueda H, Etoh T, Koike E, Fujinami N, Mitsuhashi A, Hoshiai H. Watanabe Y, et al. Among authors: hoshiai h. Anticancer Res. 2007 May-Jun;27(3B):1449-52. Anticancer Res. 2007. PMID: 17595760 Free article.

6

Feasibility study of docetaxel and nedaplatin for recurrent squamous cell carcinoma of the uterine cervix.

Watanabe Y, Nakai H, Etoh T, Kanemura K, Tsuji I, Ishizu A, Hoshiai H. Watanabe Y, et al. Among authors: hoshiai h. Anticancer Res. 2008 Jul-Aug;28(4C):2385-8. Anticancer Res. 2008. PMID: 18751423 Free article. Clinical Trial.

7

Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer.

Watanabe Y, Etoh T, Koike E, Mizuno Y, Wang WM, Hoshiai H. Watanabe Y, et al. Among authors: hoshiai h. Int J Clin Oncol. 2010 Oct;15(5):468-71. doi: 10.1007/s10147-010-0094-1. Epub 2010 May 18. Int J Clin Oncol. 2010. PMID: 20480200

8

Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.

Watanabe Y, Nakai H, Ueda H, Nozaki K, Hoshiai H. Watanabe Y, et al. Among authors: hoshiai h. Int J Gynecol Cancer. 2005 Mar-Apr;15(2):224-7. doi: 10.1111/j.1525-1438.2005.15207.x. Int J Gynecol Cancer. 2005. PMID: 15823103 Free article.

9

Platelet-derived endothelial cell growth factor predicts of progression and recurrence in primary epithelial ovarian cancer.

Watanabe Y, Nakai H, Ueda H, Nozaki K, Hoshiai H, Noda K. Watanabe Y, et al. Among authors: hoshiai h. Cancer Lett. 2003 Oct 28;200(2):173-6. doi: 10.1016/s0304-3835(03)00413-0. Cancer Lett. 2003. PMID: 14568172

10

[Hemoglobin level and recurrent rate of uterine cervical cancer].

Ueda H, Watanabe Y, Hoshiai H. Ueda H, et al. Among authors: hoshiai h. Nihon Rinsho. 2004 Oct;62 Suppl 10:222-4. Nihon Rinsho. 2004. PMID: 15535239 Review. Japanese. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

159 results

Search Page

Filters